Comerica Securities’s Bristol-Myers Squibb BMY Stock Holding History

Comerica Securities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$935K	Sell	16,108 -13	-0.1%	-$797	0.08%	211
2023 Q2	$1.03M	Sell	16,121 -1,943	-11%	-$130K	0.07%	225
2023 Q1	$1.25M	Buy	18,064 +361	+2%	+$25.5K	0.09%	198
2022 Q4	$1.27M	Buy	17,703 +1,504	+9%	+$113K	0.09%	194
2022 Q3	$1.15M	Sell	16,199 -2,075	-11%	-$151K	0.09%	191
2022 Q2	$1.42M	Buy	18,274 +1,645	+10%	+$125K	0.11%	182
2022 Q1	$1.22M	Buy	16,629 +5,907	+55%	+$397K	0.08%	199
2021 Q4	$669K	Sell	10,722 -15,128	-59%	-$887K	0.04%	285
2021 Q3	$1.54M	Buy	25,850 +1,467	+6%	+$96.6K	0.11%	172
2021 Q2	$1.63M	Sell	24,383 -1,109	-4%	-$72.3K	0.12%	150
2021 Q1	$1.62M	Sell	25,492 -2,481	-9%	-$154K	0.12%	154
2020 Q4	$1.75M	Buy	27,973 +24	+0.1%	+$1.48K	0.14%	137
2020 Q3	$1.69M	Buy	27,949 +1,019	+4%	+$61.3K	0.15%	128
2020 Q2	$1.58M	Sell	26,930 -12,429	-32%	-$743K	0.15%	133
2020 Q1	$2.19M	Buy	39,359 +28,603	+266%	+$1.75M	0.25%	101
2019 Q4	$690K	Buy	10,756 +2,866	+36%	+$164K	0.07%	256
2019 Q3	$400K	Buy	7,890 +849	+12%	+$39.9K	0.04%	307
2019 Q2	$319K	Buy	7,041 +699	+11%	+$32.6K	0.03%	329
2019 Q1	$303K	Buy	6,342 +295	+5%	+$14.7K	0.03%	338
2018 Q4	$314K	Buy	6,047 +409	+7%	+$22K	0.04%	313
2018 Q3	$350K	Buy	5,638 +328	+6%	+$19.5K	0.04%	323
2018 Q2	$294K	Sell	5,310 -120	-2%	-$6.48K	0.04%	343
2018 Q1	$343K	Buy	5,430 +201	+4%	+$12.9K	0.04%	308
2017 Q4	$320K	Sell	5,229 -130	-2%	-$8.13K	0.04%	321
2017 Q3	$342K	Sell	5,359 -39	-0.7%	-$2.28K	0.05%	305
2017 Q2	$301K	Buy	5,398 +228	+4%	+$12.4K	0.04%	317
2017 Q1	$281K	Sell	5,170 -820	-14%	-$45K	0.04%	324
2016 Q4	$350K	Buy	+5,990	New	+$327K	0.15%	157
2016 Q3	–	Sell	-5,186	Closed	-$381K	–	217
2016 Q2	$381K	Buy	5,186 +174	+3%	+$12.3K	0.19%	120
2016 Q1	$320K	Buy	+5,012	New	+$316K	0.17%	126

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Comerica Securities's BMY Position: Q3 2023 in Review

Comerica Securities reduced its Bristol-Myers Squibb (BMY) stake by 0.08% in Q3 2023, selling an estimated $797 and leaving 16,108 shares worth $935K. The position accounts for 0.08% of the portfolio, ranked #211.

Comerica Securities first reported a position in BMY in Q1 2016 and has held it in 30 quarters since. The position peaked at $2.19M in Q1 2020. 2,387 funds tracked by Wall St. Rank hold BMY as of Q3 2023.

Comerica Securities held 16,108 shares of Bristol-Myers Squibb worth $935K as of Q3 2023.
Comerica Securities sold 13 Bristol-Myers Squibb shares in Q3 2023, an estimated $797.
Bristol-Myers Squibb made up 0.08% of Comerica Securities's portfolio in Q3 2023, its #211 holding.
Comerica Securities first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 30 quarters since.
Comerica Securities's Bristol-Myers Squibb position peaked at $2.19M in Q1 2020.
2,387 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.

Based on Comerica Securities's 13F filing for Q3 2023, filed 26 Oct 2023.